MX2021010568A - Leucina, acetilleucina y analogos relacionados para el tratamiento de enfermedades. - Google Patents

Leucina, acetilleucina y analogos relacionados para el tratamiento de enfermedades.

Info

Publication number
MX2021010568A
MX2021010568A MX2021010568A MX2021010568A MX2021010568A MX 2021010568 A MX2021010568 A MX 2021010568A MX 2021010568 A MX2021010568 A MX 2021010568A MX 2021010568 A MX2021010568 A MX 2021010568A MX 2021010568 A MX2021010568 A MX 2021010568A
Authority
MX
Mexico
Prior art keywords
leucine
pharmaceutically acceptable
acceptable salt
acetyl
treating disease
Prior art date
Application number
MX2021010568A
Other languages
English (en)
Spanish (es)
Inventor
Mallory Factor
Taylor Fields
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of MX2021010568A publication Critical patent/MX2021010568A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2021010568A 2019-03-02 2020-03-02 Leucina, acetilleucina y analogos relacionados para el tratamiento de enfermedades. MX2021010568A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962812987P 2019-03-02 2019-03-02
US201962842296P 2019-05-02 2019-05-02
US201962888894P 2019-08-19 2019-08-19
US201962895144P 2019-09-03 2019-09-03
PCT/IB2020/051767 WO2020178721A1 (en) 2019-03-02 2020-03-02 Leucine, acetyl leucine, and related analogs for treating disease

Publications (1)

Publication Number Publication Date
MX2021010568A true MX2021010568A (es) 2021-11-12

Family

ID=69845470

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021010568A MX2021010568A (es) 2019-03-02 2020-03-02 Leucina, acetilleucina y analogos relacionados para el tratamiento de enfermedades.
MX2024015063A MX2024015063A (es) 2019-03-02 2021-09-02 Leucina, acetilleucina y analogos relacionados para el tratamiento de enfermedades

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024015063A MX2024015063A (es) 2019-03-02 2021-09-02 Leucina, acetilleucina y analogos relacionados para el tratamiento de enfermedades

Country Status (25)

Country Link
US (1) US20220142959A1 (cg-RX-API-DMAC10.html)
EP (2) EP4464378A3 (cg-RX-API-DMAC10.html)
JP (2) JP7555346B2 (cg-RX-API-DMAC10.html)
KR (2) KR102941068B1 (cg-RX-API-DMAC10.html)
CN (2) CN119097618A (cg-RX-API-DMAC10.html)
AU (2) AU2020231189B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021017203A2 (cg-RX-API-DMAC10.html)
CA (1) CA3131948A1 (cg-RX-API-DMAC10.html)
DK (1) DK3934637T3 (cg-RX-API-DMAC10.html)
ES (1) ES2990183T3 (cg-RX-API-DMAC10.html)
FI (1) FI3934637T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20241150T1 (cg-RX-API-DMAC10.html)
HU (1) HUE068527T2 (cg-RX-API-DMAC10.html)
IL (2) IL321899A (cg-RX-API-DMAC10.html)
LT (1) LT3934637T (cg-RX-API-DMAC10.html)
MA (1) MA55199B1 (cg-RX-API-DMAC10.html)
MD (1) MD3934637T2 (cg-RX-API-DMAC10.html)
MX (2) MX2021010568A (cg-RX-API-DMAC10.html)
PL (1) PL3934637T3 (cg-RX-API-DMAC10.html)
PT (1) PT3934637T (cg-RX-API-DMAC10.html)
RS (1) RS65849B1 (cg-RX-API-DMAC10.html)
SG (1) SG11202109512SA (cg-RX-API-DMAC10.html)
SI (1) SI3934637T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202400334T1 (cg-RX-API-DMAC10.html)
WO (1) WO2020178721A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
CN120157593A (zh) 2018-12-06 2025-06-17 内在生物技术有限公司 乙酰基-亮氨酸的氘代类似物
MD3989962T2 (ro) 2019-06-28 2025-12-31 Intrabio Ltd Gb Terapie combinată cu acetil-leucină și miglustat pentru tratamentul unei boli de depozitare lizozomală
WO2021144720A1 (en) 2020-01-13 2021-07-22 Intrabio Ltd Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers
WO2022125304A1 (en) * 2020-12-10 2022-06-16 Texas Tech University System Bcaa-lowering compounds for prevention and/or treatment of alzheimer's disease and related disorders
WO2022264037A1 (en) * 2021-06-14 2022-12-22 Intrabio Ltd. Branched-chain amino acid derivatives to treat disease
WO2024243004A2 (en) * 2023-05-19 2024-11-28 The Children's Hospital Of Philadelphia Compositions and methods for treating traumatic brain injury
WO2025166100A1 (en) * 2024-02-02 2025-08-07 SynGAP Research Fund Compositions and methods for treating neurodevelopmental disorders
WO2025175092A1 (en) * 2024-02-14 2025-08-21 Intrabio Inc. Acetyl leucine for treating syngap1-related disorders
TW202604470A (zh) * 2024-06-20 2026-02-01 美商音特拉拜歐公司 乙醯白胺酸用於治療神經發育障礙

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063827A1 (en) * 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
FR2905600B1 (fr) * 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
CA2803166C (en) 2010-06-25 2023-03-07 Shire Human Genetic Therapies, Inc. Cns delivery of therapeutic agents
US20140080885A1 (en) * 2012-09-13 2014-03-20 University Of South Florida (A Florida Non-Profit Corporation) Methods of treating traumatic brain injury
PT3445351T (pt) * 2016-04-19 2024-11-14 Intrabio Ltd Acetil-leucina ou um sal farmaceuticamente aceitável seu derivado para melhoria da mobilidade
TN2016000259A1 (en) * 2016-06-27 2017-10-06 Rekik Raouf Salbutamol (albuterol) eye protective medicament.
PT3482754T (pt) 2016-08-11 2021-02-03 Intrabio Ltd Composições farmacêuticas e utilizações contra os distúrbios de armazenamento lisossómico
TN2019000033A1 (fr) * 2016-08-11 2020-07-15 Intrabio Ltd Agents thérapeutiques pour maladies neurodégénératives
US20190046486A1 (en) * 2017-08-14 2019-02-14 Axcella Health Inc. Compositions and methods for the treatment of neuronal injury

Also Published As

Publication number Publication date
CA3131948A1 (en) 2020-09-10
EP3934637A1 (en) 2022-01-12
RS65849B1 (sr) 2024-09-30
SMT202400334T1 (it) 2024-09-16
HRP20241150T1 (hr) 2024-11-22
AU2020231189A1 (en) 2021-09-30
MA55199A (fr) 2022-01-12
AU2025204995A1 (en) 2025-07-17
EP4464378A3 (en) 2025-04-09
EP3934637B1 (en) 2024-07-31
CN114040757B (zh) 2024-09-20
KR102941068B1 (ko) 2026-03-18
MA55199B1 (fr) 2024-08-30
MD3934637T2 (ro) 2024-12-31
JP2024170602A (ja) 2024-12-10
PT3934637T (pt) 2024-08-30
WO2020178721A1 (en) 2020-09-10
IL285870B1 (en) 2025-08-01
BR112021017203A2 (pt) 2021-12-14
CN119097618A (zh) 2024-12-10
CN114040757A (zh) 2022-02-11
PL3934637T3 (pl) 2024-10-14
JP7555346B2 (ja) 2024-09-24
IL321899A (en) 2025-09-01
FI3934637T3 (fi) 2024-09-02
US20220142959A1 (en) 2022-05-12
EP4464378A2 (en) 2024-11-20
IL285870A (en) 2021-10-31
MX2024015063A (es) 2025-01-09
LT3934637T (lt) 2024-08-26
JP2022522819A (ja) 2022-04-20
ES2990183T3 (es) 2024-11-29
AU2020231189B2 (en) 2025-07-24
KR20250171484A (ko) 2025-12-08
HUE068527T2 (hu) 2025-01-28
IL285870B2 (en) 2025-12-01
DK3934637T3 (da) 2024-09-02
SG11202109512SA (en) 2021-09-29
KR20210135272A (ko) 2021-11-12
SI3934637T1 (sl) 2024-10-30

Similar Documents

Publication Publication Date Title
MX2024015063A (es) Leucina, acetilleucina y analogos relacionados para el tratamiento de enfermedades
MX2025005489A (es) Uso de lumateperona para el tratamiento del trastorno bipolar ii
WO2018218070A3 (en) COVALENT INHIBITORS OF KRAS
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
MX2025001920A (es) Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina
SA520411843B1 (ar) Trpc6 مشتقات بيريدين كربونيل والاستخدام الطبي لها كمثبطات
EA201492010A1 (ru) Применение высокой дозы лахинимода для лечения рассеянного склероза
EP3970712A3 (en) Solid oral dosage forms of 2r,6r-hydroxynorketamine or derivatives thereof
EA202193190A1 (ru) Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов
WO2012142615A3 (en) Auranofin and auranofin analogs useful to treat proliferative disease and disorders
EP4298093A4 (en) ANALOGUES FOR THE TREATMENT OF DISEASE
MX2019003470A (es) Composicion farmaceutica y metodo para el tratamiento de la enfermedad del higado graso no alcoholico.
WO2015047982A3 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
AU2024216821A1 (en) Rifabutin analogs for the treatment of bacterial diseases
HK1255584A1 (zh) 使用阿坎酸及d-环丝胺酸的联合疗法
EP4585269A3 (en) Methods for cancer therapy
MX2022006052A (es) Inhibidores de la caspasa 6 y usos de los mismos.
CA3266876A1 (en) RIFABUTINE ANALOGUES FOR THE TREATMENT OF A DISEASE
EP4389218A3 (en) Composition for treating joint disease and kit containing same
PH12020550722A1 (en) Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye
PH12018500469A1 (en) Sulfonamide compounds as voltage-gated sodium channel modulators
WO2016122288A3 (ko) 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제
EP4414029A3 (en) Methods of use for kv7 channel activators
WO2016130518A3 (en) Methods and compositions for treating muscle disease and disorders
MX2021014093A (es) Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson.